News

  1. DaVita Clinical Research Launches New Advisory Committee Preparation Services 9/28/2011
    DaVita Clinical Research (DCR), a provider of clinical research services focused on kidney research as well as a multitude of specialty therapeutic populations, will launch their new Advisory Committee Preparation Services at the 2011 Regulatory Affairs Professionals Society (RAPS): The Regulatory Convergence.
  2. Trident Pharmaceuticals Announces Initiation Of Phase 1a Clinical Study Of HF1020 9/21/2011
    Trident Pharmaceuticals Inc., a biotechnology company developing therapies for autoimmune diseases and allergic conditions, today announced the initiation of a Phase 1a study for HF1020, a first in class recombinant protein with immunomodulatory activity.
  3. Ultrasensitive Particles Offer New Way To Find Cancer 9/2/2011
    About 10 years ago, scientists discovered a new type of genetic material called microRNA, which appears to turn genes on or off inside a cell. More recently, they found that these genetic snippets often go haywire in cancer cells, contributing to tumors’ uncontrollable growth.
  4. Afexa Announces Results Of A Clinical Trial Of Dilexaponan™ For Cholesterol Management 8/23/2011
    Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) - the maker of COLD-FX® - today announced promising results of a pilot clinical study investigating the effects of a new formulation, Dilexaponan™ (LIP-01) on cholesterol management.
  5. MELA Sciences Issues Statement On FDA's New Draft Guidance On Pivotal Clinical Trials 8/23/2011
    MELA Sciences, Inc. issued the following statement regarding the U.S. Food and Drug Administration’s (FDA) draft guidance on Design Considerations for Pivotal Clinical Investigations for Medical Devices, including those conducted to support Premarket Approval (PMA) applications.
  6. DOE Laboratories Help Develop Promising New Cancer Fighting Drug, Vemurafenib 8/22/2011
    Powerful X-ray technology developed at the U.S. Department of Energy’s (DOE’s) national laboratories is revealing new insights into diseases ranging from Alzheimer’s to the swine flu, and, most recently, enabled the discovery of a groundbreaking new drug treatment for malignant melanoma, the deadliest form of skin cancer.
  7. First Gene-Targeted Drug For Melanoma Approved By FDA 8/18/2011
    Melanoma patients who have long faced a bleak treatment landscape are gaining a new approach for treating the deadliest form of skin cancer. The Food and Drug Administration today announced the approval of Zelboraf, known as vemurafenib or PLX4032 during testing, well ahead of the approval deadline.
  8. Genetically Modified "Serial Killer" T Cells Obliterate Tumors In Patients With Chronic Lymphocytic Leukemia, Penn Researchers Report 8/12/2011
    In a cancer treatment breakthrough 20 years in the making, researchers from the University of Pennsylvania's Abramson Cancer Center and Perelman School of Medicine have shown sustained remissions of up to a year among a small group of advanced chronic lymphocytic leukemia (CLL) patients treated with genetically engineered versions of their own T cells.
  9. XOMA Reports Second Quarter 2011 Financial Results 8/8/2011
    XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, today announced its financial results for the second quarter and six months ended June 30, 2011 and provided a general business update.
  10. Amarantus BioSciences And Generex Biotechnology Collaborate On Cell Therapy For Late Stage Diabetes 8/5/2011
    Amarantus BioSciences, a biotechnology company developing a first-in-class anti-apoptosis therapeutic protein known as MANF, and Generex Biotechnology, a biotechnology company developing a buccal insulin spray technology known as Generex Oral-lyn, currently in a Phase III trial, recently are making public the details of their intended third joint diabetes research collaboration.